Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph early_phase_1
2
50%
Ph phase_1
1
25%
Ph not_applicable
1
25%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
2(50.0%)
Phase 1Safety & dosage
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated1
Completed1
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (50.0%)
Phase 11 (25.0%)
N/A1 (25.0%)

Trials by Status

terminated125%
completed125%
withdrawn125%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_1

A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge

NCT05884242
recruitingnot_applicable

Mapping the Effect of (neuro)inflammation on Stress Sensitivity in the Brain of Healthy Men

NCT06620679
terminatedearly_phase_1

Leucine for Depression Study (L-DEP)

NCT03557684
withdrawnearly_phase_1

Theophylline for Depression Study

NCT04309877

Clinical Trials (4)

Showing 4 of 4 trials
NCT05884242Phase 1

A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge

Completed
NCT06620679Not Applicable

Mapping the Effect of (neuro)inflammation on Stress Sensitivity in the Brain of Healthy Men

Recruiting
NCT03557684Early Phase 1

Leucine for Depression Study (L-DEP)

Terminated
NCT04309877Early Phase 1

Theophylline for Depression Study

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4